[Form 4] Travere Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Peter Heerma, Chief Commercial Officer of Travere Therapeutics (TVTX), reported a charitable gift of 891 shares of common stock on 09/23/2025. The gift was made to a donor advised fund under a written plan adopted on June 16, 2025 and is described as complying with Rule 10b5-1(c). After the transaction, Heerma beneficially owned 127,324 shares of Travere common stock. The Form 4 was signed by attorney-in-fact Elizabeth E. Reed on 09/24/2025. The filing indicates the transaction was a non-derivative, zero-price disposition (charitable transfer) and does not report any exercise, purchase, or sale for cash.

Insights

Corporate Governance Expert

TL;DR: A routine, compliant charitable transfer under a pre-existing 10b5-1 plan; immaterial to shareholder control.

The filing documents a donation of 891 shares by an officer under a written 10b5-1(c) plan adopted June 16, 2025, suggesting pre-planned disposition to avoid timing concerns. The transaction reduced beneficial holdings to 127,324 shares. No derivatives or cash sales are reported. From a governance perspective, this is a standard disclosure that maintains compliance with Section 16 reporting requirements and indicates no change in ownership intent or control arising from the transfer.

Securities/Compliance Analyst

TL;DR: Disclosure is clear and procedurally compliant; the transfer is non-material in size relative to total holdings.

The Form 4 shows a non-derivative disposition coded G(1) for a charitable gift executed 09/23/2025. The description explicitly ties the gift to a donor advised fund and a 10b5-1(c) written plan. The signature by an attorney-in-fact and the inclusion of exact share counts meet filing standards. There are no indications of additional transactions or amendments in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Heerma Peter

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, SUITE 300

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF COMMERCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/23/2025		G(1)		891	D	$0	127,324	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction represents a charitable gift of 891 shares of common stock to a donor advised fund, which was gifted pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Travere (TVTX) insider Peter Heerma report on Form 4?

He reported a charitable gift of 891 shares of Travere common stock dated 09/23/2025, reducing beneficial holdings to 127,324 shares.

Was the 891-share transfer part of a trading plan?

Yes. The gift was made pursuant to a written plan adopted on June 16, 2025 that the filer states meets the requirements of Rule 10b5-1(c).

What type of transaction code is used in the filing?

The filing uses transaction code G(1), indicating a donation or gift of shares.

Who signed the Form 4 and when?

The Form 4 was signed by Elizabeth E. Reed, Attorney-in-Fact on 09/24/2025.

Did the filing report any derivative transactions or cash sales?

No. The filing shows a non-derivative disposition (charitable gift) at a reported price of $0 and lists no derivative activity.